US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
US6429221B1
(en)
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
US5635517B1
(en)
|
1996-07-24 |
1999-06-29 |
Celgene Corp |
Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
UA60308C2
(uk)
*
|
1996-07-24 |
2003-10-15 |
Селджін Корпорейшн |
ЗАМІЩЕНІ 2-(2,6-ДІОКСОПІПЕРИДИН-3-ІЛ)ФТАЛІМІДИ ТА 1-ОКСОІЗОІНДОЛІНИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЗНИЖЕННЯ РІВНЯ ФПН-α
|
DE19703763C1
(de)
*
|
1997-02-01 |
1998-10-01 |
Gruenenthal Gmbh |
Thalidomidanaloge Verbindungen aus der Klasse der Piperidin-2,6-Dione
|
US5955476A
(en)
*
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
ES2262753T3
(es)
*
|
1997-11-18 |
2006-12-01 |
Celgene Corporation |
2-(2.6-dioxo-3-fluorpiperidin-3-il)-isoindolinas substituidas y su empleo para reducir los niveles de tnfalfa.
|
TR200101502T2
(tr)
*
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
|
WO2000055134A1
(en)
|
1999-03-18 |
2000-09-21 |
Celgene Corporation |
Substituted 1-oxo- and 1,3-dioxoisoindolines and their use in pharmaceutical compositions for reducing inflammatory cytokine levels
|
DE19917195B4
(de)
*
|
1999-04-16 |
2006-09-28 |
Immatics Biotechnologies Gmbh |
Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
US7182953B2
(en)
*
|
1999-12-15 |
2007-02-27 |
Celgene Corporation |
Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
NZ526683A
(en)
*
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
AU2002221096A1
(en)
*
|
2000-12-11 |
2002-06-24 |
Takeda Chemical Industries Ltd. |
Medicinal compositions improved in solublity in water
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
US20030045552A1
(en)
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
AU2002306596B2
(en)
*
|
2001-02-27 |
2008-01-17 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Analogs of thalidomide as potential angiogenesis inhibitors
|
DE60231989D1
(de)
*
|
2001-08-06 |
2009-05-28 |
Childrens Medical Center |
Antiangiogenese wirkung von stickstoffsubstituierten thalidomid-analoga
|
US7498171B2
(en)
|
2002-04-12 |
2009-03-03 |
Anthrogenesis Corporation |
Modulation of stem and progenitor cell differentiation, assays, and uses thereof
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
KR100793564B1
(ko)
|
2002-05-17 |
2008-01-14 |
셀진 코포레이션 |
암 및 기타 질병의 치료 및 관리를 위해 면역 조절화합물을 이용하는 방법 및 조성물
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8404717B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
FR2845994B1
(fr)
*
|
2002-10-18 |
2006-05-19 |
Servier Lab |
Nouveaux derives de benzo[e][1,4]oxazino[3,2-g]isoindole substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
CA2503536A1
(en)
*
|
2002-10-24 |
2004-05-06 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
CA2504024A1
(en)
*
|
2002-10-31 |
2004-05-21 |
Celgene Corporation |
Composition for the treatment of macular degeneration
|
US7563810B2
(en)
*
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
CH696542A5
(de)
*
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
UA83504C2
(en)
*
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US8952895B2
(en)
|
2011-06-03 |
2015-02-10 |
Apple Inc. |
Motion-based device operations
|
CA2538864C
(en)
|
2003-09-17 |
2013-05-07 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Thalidomide analogs as tnf-alpha modulators
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
US20050100529A1
(en)
*
|
2003-11-06 |
2005-05-12 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders
|
EP2505200A1
(en)
|
2004-03-22 |
2012-10-03 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of scleroderma
|
US20090163548A1
(en)
*
|
2004-05-05 |
2009-06-25 |
Zeldis Jerome B |
Method of using and comopositions comprising immunomodulatory compounds for the treatment and management of myeloproliferative diseases
|
NZ554068A
(en)
|
2004-09-03 |
2009-07-31 |
Celgene Corp |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
|
ME01513B
(me)
|
2005-06-30 |
2014-04-20 |
Celgene Corp |
Postupak dobijanja spojeva 4-amin0-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
|
WO2007009062A2
(en)
|
2005-07-13 |
2007-01-18 |
Anthrogenesis Corporation |
Treatment of leg ulcers using placenta derived collagen biofabric
|
MX2008002765A
(es)
|
2005-08-31 |
2008-04-07 |
Celgene Corp |
Compuestos de isoindol-imida y composiciones que la comprenden y metodos para usar los mismos.
|
CA2621136C
(en)
|
2005-09-01 |
2014-10-14 |
Celgene Corporation |
Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
CN1939922B
(zh)
*
|
2005-09-27 |
2010-10-13 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的5H-噻吩[3,4-c]吡咯-4,6-二酮衍生物
|
EP1974013A2
(en)
*
|
2005-12-29 |
2008-10-01 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
CA2646316C
(en)
|
2006-03-15 |
2016-05-24 |
Theralogics, Inc. |
Methods of treating muscular wasting diseases using nf-kb activation inhibitors
|
US20080064876A1
(en)
*
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
CL2007002218A1
(es)
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
WO2008021391A1
(en)
|
2006-08-15 |
2008-02-21 |
Anthrogenesis Corporation |
Umbilical cord biomaterial for medical use
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
MX2009001989A
(es)
*
|
2006-08-30 |
2009-03-09 |
Celgene Corp |
Compuestos de isoindolina 5-substituidos.
|
DK2066656T3
(da)
*
|
2006-09-26 |
2012-05-21 |
Celgene Corp |
5-substituerede quinazolinonderivater som antitumor-midler
|
EP1923053A1
(en)
|
2006-09-27 |
2008-05-21 |
Novartis AG |
Pharmaceutical compositions comprising nilotinib or its salt
|
WO2008060377A2
(en)
|
2006-10-04 |
2008-05-22 |
Anthrogenesis Corporation |
Placental or umbilical cord tissue compositions
|
CA3178363A1
(en)
|
2006-10-06 |
2008-05-15 |
Celularity Inc. |
Human placental collagen compositions, and methods of making and using the same
|
CA2704710C
(en)
|
2007-09-26 |
2016-02-02 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same
|
US20090088393A1
(en)
*
|
2007-09-28 |
2009-04-02 |
Zomanex, Llc |
Methods and formulations for converting intravenous and injectable drugs into oral dosage forms
|
EP2783692B1
(en)
|
2007-09-28 |
2019-01-02 |
Celularity, Inc. |
Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
|
CA2704663A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction
|
EP2235213A2
(en)
|
2007-12-20 |
2010-10-06 |
Celgene Corporation |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
US20110021567A1
(en)
*
|
2008-03-11 |
2011-01-27 |
Dr. Reddy's Laboratories Ltd. |
Preparation of lenalidomide
|
CN101531653B
(zh)
*
|
2008-03-13 |
2014-07-09 |
峡江和美药业有限公司 |
3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用
|
US20110060010A1
(en)
*
|
2008-03-13 |
2011-03-10 |
Tianjin Hemay Bio-Tech Co., Ltd |
Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof
|
WO2009139880A1
(en)
*
|
2008-05-13 |
2009-11-19 |
Celgene Corporation |
Thioxoisoindoline compounds and compositions and methods of using the same
|
PE20140963A1
(es)
|
2008-10-29 |
2014-08-06 |
Celgene Corp |
Compuestos de isoindolina para el tratamiento de cancer
|
DE102008057335A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Amorphes Lenalidomid
|
US9045453B2
(en)
|
2008-11-14 |
2015-06-02 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
DE102008057284A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
|
EA201391720A1
(ru)
*
|
2008-11-14 |
2014-04-30 |
Консерт Фармасьютикалс Инк. |
Замещенные диоксопиперидинилфталимидные производные
|
DE102008057285A1
(de)
|
2008-11-14 |
2010-05-20 |
Ratiopharm Gmbh |
3-(4-Amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-2,6-piperidindion in Form einer festen Lösung
|
US20120053159A1
(en)
|
2009-02-11 |
2012-03-01 |
Muller George W |
Isotopologues of lenalidomide
|
NZ595440A
(en)
|
2009-03-25 |
2014-05-30 |
Anthrogenesis Corp |
Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
|
RU2479307C1
(ru)
|
2009-05-19 |
2013-04-20 |
Селджин Корпорейшн |
Композиция 4-амино-2-(2,6-диоксопиперидин-3-ил)изоиндолин-1,3-диона
|
WO2010137547A1
(ja)
|
2009-05-25 |
2010-12-02 |
国立大学法人東京工業大学 |
中枢神経細胞の増殖及び分化に係る中核因子を含む医薬組成物
|
CN101580501B
(zh)
*
|
2009-06-01 |
2011-03-09 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚酮-2-基)-2,6-哌啶二酮的合成方法及其中间体
|
US20120184746A1
(en)
|
2009-09-03 |
2012-07-19 |
Ranbaxy Laboratories Limited |
Process for the preparation of lenalidomide
|
WO2011050962A1
(en)
|
2009-10-29 |
2011-05-05 |
Ratiopharm Gmbh |
Acid addition salts of lenalidomide
|
CN101696205B
(zh)
|
2009-11-02 |
2011-10-19 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
CN102127054B
(zh)
*
|
2009-11-02 |
2013-04-03 |
南京卡文迪许生物工程技术有限公司 |
3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物
|
WO2011069608A1
(en)
|
2009-12-09 |
2011-06-16 |
Ratiopharm Gmbh |
S-lenalidomide, polymorphic forms thereof and blend comprising s- und r-lenalidomide
|
JP5760008B2
(ja)
|
2009-12-22 |
2015-08-05 |
セルジーン コーポレイション |
(メチルスルホニル)エチルベンゼンイソインドリン誘導体及びその治療的使用
|
CA2786266A1
(en)
|
2010-01-05 |
2011-07-14 |
Celgene Corporation |
A combination of an immunomodulatory compound and an artemisinin or a derivative thereof for treating cancer
|
DK2536706T3
(en)
|
2010-02-11 |
2017-08-14 |
Celgene Corp |
ARYLMETHOXYISOINDOLINE DERIVATIVES AND COMPOSITIONS COMPREHENSIVE AND PROCEDURES FOR USING SAME
|
MX341050B
(es)
|
2010-04-07 |
2016-08-05 |
Celgene Corp * |
Metodos para tratar infeccion viral respiratoria.
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
JP6132773B2
(ja)
|
2011-01-10 |
2017-05-24 |
セルジーン コーポレイション |
Pde4及び/又はサイトカインの阻害剤としてのフェネチルスルホンイソインドリン誘導体
|
PE20140983A1
(es)
|
2011-03-11 |
2014-08-25 |
Celgene Corp |
Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos
|
US9090585B2
(en)
|
2011-03-28 |
2015-07-28 |
Deuterx, Llc |
2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds
|
WO2012145309A1
(en)
|
2011-04-18 |
2012-10-26 |
Celgene Corporation |
Biomarkers for the treatment of multiple myeloma
|
US9365640B2
(en)
|
2011-04-29 |
2016-06-14 |
Celgene Corporation |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
US20140221427A1
(en)
|
2011-06-22 |
2014-08-07 |
Celgene Corporation |
Isotopologues of pomalidomide
|
JP2014526508A
(ja)
|
2011-09-14 |
2014-10-06 |
セルジーン コーポレイション |
シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの製剤
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
CA2861594A1
(en)
|
2011-12-27 |
2013-07-04 |
Celgene Corporation |
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione
|
US9085551B2
(en)
*
|
2012-02-21 |
2015-07-21 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione
|
JP2015520179A
(ja)
|
2012-06-06 |
2015-07-16 |
ビオノール イミュノ エーエスBionor Immuno As |
ワクチン
|
CA3136093A1
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
AR094997A1
(es)
|
2012-08-09 |
2015-09-16 |
Celgene Corp |
Sales y formas sólidas de (s)-3-(4-((4-(morfolinometil)bencil)oxi)-1-oxoisoindolin-2-il)piperidin-2,6-diona y composiciones que las comprenden y sus usos
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
US9643950B2
(en)
|
2012-10-22 |
2017-05-09 |
Concert Pharmaceuticals, Inc. |
Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione}
|
AU2013204922B2
(en)
|
2012-12-20 |
2015-05-14 |
Celgene Corporation |
Chimeric antigen receptors
|
FR2999914B1
(fr)
*
|
2012-12-21 |
2015-08-07 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique pour traiter les alterations de la peau liees a l'age ou au photovieillissement
|
FR2999915B1
(fr)
*
|
2012-12-21 |
2017-08-11 |
Oreal |
Utilisation de derives de l'acide imidocarboxylique en tant qu'agent apaisant
|
WO2014110322A2
(en)
|
2013-01-11 |
2014-07-17 |
Concert Pharmaceuticals, Inc. |
Substituted dioxopiperidinyl phthalimide derivatives
|
AU2014205043B2
(en)
|
2013-01-14 |
2018-10-04 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
AU2014215458A1
(en)
|
2013-02-05 |
2015-08-13 |
Anthrogenesis Corporation |
Natural killer cells from placenta
|
EP2764866A1
(en)
|
2013-02-07 |
2014-08-13 |
IP Gesellschaft für Management mbH |
Inhibitors of nedd8-activating enzyme
|
JP6493692B2
(ja)
|
2013-03-15 |
2019-04-10 |
セルジーン コーポレイション |
修飾されたtリンパ球
|
CN104072476B
(zh)
*
|
2013-03-27 |
2018-08-21 |
江苏豪森药业集团有限公司 |
泊马度胺晶型及其制备方法和用途
|
WO2014172429A1
(en)
|
2013-04-17 |
2014-10-23 |
Signal Pharmaceuticals, Llc |
Combination therapy comprising a tor kinase inhibitor and an imid compound for treating cancer
|
EP2815749A1
(en)
*
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
WO2015007337A1
(en)
|
2013-07-19 |
2015-01-22 |
Bionor Immuno As |
Method for the vaccination against hiv
|
CN103497174B
(zh)
*
|
2013-07-29 |
2015-10-28 |
杭州派臣医药科技有限公司 |
泊利度胺的制备和精制方法
|
CN104557857A
(zh)
*
|
2013-10-29 |
2015-04-29 |
上海医药工业研究院 |
一种泊利度胺的纯化方法
|
CN104557858B
(zh)
*
|
2013-10-29 |
2018-06-01 |
上海医药工业研究院 |
一种泊利度胺的制备方法
|
CN105939716A
(zh)
|
2013-12-03 |
2016-09-14 |
埃斯泰隆制药公司 |
组蛋白脱乙酰基酶抑制剂和免疫调节药物的组合
|
CN104016967A
(zh)
*
|
2014-04-04 |
2014-09-03 |
南京工业大学 |
一种泊利度胺的合成方法
|
EP3131588A4
(en)
*
|
2014-04-14 |
2018-01-10 |
Arvinas, Inc. |
Imide-based modulators of proteolysis and associated methods of use
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
CN109678840B
(zh)
*
|
2014-08-20 |
2023-12-01 |
河北菲尼斯生物技术有限公司 |
泊马度胺的制备方法
|
EP3182996B1
(en)
|
2014-08-22 |
2022-12-28 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
CN105440013B
(zh)
*
|
2014-08-29 |
2018-10-09 |
杭州和泽医药科技有限公司 |
一种泊马度胺的制备方法
|
ES2812877T3
(es)
*
|
2014-10-30 |
2021-03-18 |
Kangpu Biopharmaceuticals Ltd |
Derivado de isoindolina, producto intermedio, método de preparación, composición farmacéutica y uso del mismo
|
US10507204B2
(en)
|
2014-12-19 |
2019-12-17 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
EP3233082B1
(en)
|
2014-12-19 |
2018-12-05 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide
|
CN104447689B
(zh)
*
|
2014-12-22 |
2016-07-20 |
上海迈柏医药科技有限公司 |
来那度胺的晶型及其制备方法
|
US20170327469A1
(en)
|
2015-01-20 |
2017-11-16 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
KR20200052995A
(ko)
|
2015-01-20 |
2020-05-15 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
WO2016191178A1
(en)
|
2015-05-22 |
2016-12-01 |
Biotheryx, Inc. |
Compounds targeting proteins, compositions, methods, and uses thereof
|
WO2016197114A1
(en)
|
2015-06-05 |
2016-12-08 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
US10001483B2
(en)
|
2015-06-26 |
2018-06-19 |
Celgene Corporation |
Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF PROTEINS CONTAINING BROMODOMAIN
|
EP3393457A1
(en)
|
2015-12-22 |
2018-10-31 |
Synthon B.V. |
Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
WO2017201069A1
(en)
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
US10584101B2
(en)
|
2016-10-11 |
2020-03-10 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
CA3209295A1
(en)
|
2016-11-01 |
2018-06-07 |
Arvinas, Inc. |
Tau-protein targeting protacs and associated methods of use
|
RS64976B1
(sr)
|
2016-12-01 |
2024-01-31 |
Arvinas Operations Inc |
Derivati tetrahidronaftalena i tetrahidroizohinolina kao degradatori estrogenih receptora
|
AU2017368332A1
(en)
|
2016-12-03 |
2019-06-13 |
Juno Therapeutics, Inc. |
Methods for modulation of CAR-T cells
|
CA3046869C
(en)
|
2016-12-16 |
2022-05-17 |
Kangpu Biopharmaceuticals, Ltd. |
Combination of a benzoheterocyclic compound and an androgen receptor pathway modulator for the treatment of prostate cancer
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
US10806737B2
(en)
|
2016-12-23 |
2020-10-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
KR102564201B1
(ko)
|
2016-12-23 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
|
EP3559002A4
(en)
|
2016-12-23 |
2021-02-17 |
Arvinas Operations, Inc. |
CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
CN117551089A
(zh)
|
2017-01-26 |
2024-02-13 |
阿尔维纳斯运营股份有限公司 |
雌激素受体蛋白水解调节剂及相关使用方法
|
US20200000776A1
(en)
|
2017-02-13 |
2020-01-02 |
Kangpu Biopharmaceuticals, Ltd. |
Combination treating prostate cancer, pharmaceutical composition and treatment method
|
SG11201910143TA
(en)
|
2017-05-01 |
2019-11-28 |
Juno Therapeutics Inc |
Combination of a cell therapy and an immunomodulatory compound
|
US10093647B1
(en)
|
2017-05-26 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof
|
CA3065120A1
(en)
|
2017-06-02 |
2018-12-06 |
Juno Therapeutics, Inc. |
Articles of manufacture and methods for treatment using adoptive cell therapy
|
CA3067602A1
(en)
|
2017-06-29 |
2019-01-03 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
TWI793151B
(zh)
*
|
2017-08-23 |
2023-02-21 |
瑞士商諾華公司 |
3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
|
US10093649B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione monohydrate, compositions and methods of use thereof
|
US10093648B1
(en)
|
2017-09-22 |
2018-10-09 |
Celgene Corporation |
Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
|
US20200246393A1
(en)
|
2017-09-28 |
2020-08-06 |
Celularity, Inc. |
Tumor suppression using human placenta-derived intermediate natural killer (pink) cells in combination with an antibody
|
MA49911A
(fr)
|
2017-11-01 |
2020-06-24 |
Juno Therapeutics Inc |
Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
US20210132042A1
(en)
|
2017-11-01 |
2021-05-06 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
US11065231B2
(en)
|
2017-11-17 |
2021-07-20 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
|
US20210070845A1
(en)
|
2017-12-15 |
2021-03-11 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
EP3505158A1
(en)
|
2017-12-27 |
2019-07-03 |
KRKA, d.d., Novo mesto |
Pharmaceutical composition of lenalidomide pharmaceutically acceptable acid addition salt
|
US11452722B2
(en)
|
2018-01-11 |
2022-09-27 |
Natco Pharma Limited |
Stable pharmaceutical compositions comprising lenalidomide
|
JP2021512153A
(ja)
|
2018-01-26 |
2021-05-13 |
イエール ユニバーシティ |
タンパク質分解のイミド系モジュレーターおよび使用方法
|
EP3755718A1
(en)
|
2018-02-21 |
2020-12-30 |
Celgene Corporation |
Bcma-binding antibodies and uses thereof
|
EP3545949A1
(en)
|
2018-03-29 |
2019-10-02 |
Midas Pharma GmbH |
Oral dosage forms comprising pomalidomide crystalline form a
|
CA3095494C
(en)
|
2018-04-04 |
2023-11-07 |
Arvinas Operations, Inc. |
Modulators of proteolysis and associated methods of use
|
KR102286497B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
다양한 용량의 레날리도마이드의 경구용 정제 조성물
|
JP2021518422A
(ja)
|
2018-04-13 |
2021-08-02 |
サムヤン バイオファーマシューティカルズ コーポレイションSamyang Biopharmaceuticals Corporation |
レナリドミドを含む医薬組成物
|
KR102259798B1
(ko)
|
2018-04-13 |
2021-06-02 |
주식회사 삼양홀딩스 |
붕해가 개선된 레날리도마이드의 경구용 정제 조성물
|
WO2019199133A1
(ko)
|
2018-04-13 |
2019-10-17 |
주식회사 삼양바이오팜 |
레날리도마이드의 경구용 코팅 정제 조성물
|
KR102286500B1
(ko)
|
2018-04-13 |
2021-08-05 |
주식회사 삼양홀딩스 |
레날리도마이드를 포함하는 경구용 고형제제의 제조방법
|
US11707452B2
(en)
|
2018-08-20 |
2023-07-25 |
Arvinas Operations, Inc. |
Modulators of alpha-synuclein proteolysis and associated methods of use
|
SG11202104411VA
(en)
|
2018-11-08 |
2021-05-28 |
Juno Therapeutics Inc |
Methods and combinations for treatment and t cell modulation
|
WO2020102770A1
(en)
|
2018-11-16 |
2020-05-22 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
EP3891128A4
(en)
*
|
2018-12-05 |
2022-08-17 |
Vividion Therapeutics, Inc. |
SUBSTITUTED ISOINDOLINONES AS MODULATORS OF CEREBLON-MEDIATED NEOSUBSTRATE RECRUITMENT
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
US20230248696A1
(en)
*
|
2019-05-03 |
2023-08-10 |
Dynamic Biologics Inc. |
Lenalidomide prodrugs, polymeric conjugates, and formulations thereof, and their uses for the treatment of multiple myeloma
|
CN110343063A
(zh)
*
|
2019-08-09 |
2019-10-18 |
新乡双鹭药业有限公司 |
一种泊马度胺合成中杂质的制备方法
|
US11420956B2
(en)
|
2019-09-23 |
2022-08-23 |
Accutar Biotechnology Inc. |
Ureas having Androgen Receptor degradation activity and uses thereof
|
WO2021061644A1
(en)
*
|
2019-09-23 |
2021-04-01 |
Accutar Biotechnology Inc. |
Novel substituted quinoline-8-carbonitrile derivatives with androgen receptor degradation activity and uses thereof
|
AU2020387392A1
(en)
|
2019-11-19 |
2022-07-14 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of Helios protein
|
JP2023507570A
(ja)
|
2019-12-19 |
2023-02-24 |
アルビナス・オペレーションズ・インコーポレイテッド |
アンドロゲン受容体の標的分解のための化合物および方法
|
EP4135668B1
(en)
|
2020-04-15 |
2024-04-17 |
Tecnimede, Sociedade Técnico-Medicinal, SA |
Solid oral dosage form comprising pomalidomide
|
EP4277901A1
(en)
|
2021-01-13 |
2023-11-22 |
Monte Rosa Therapeutics, Inc. |
Isoindolinone compounds
|
BR112023020077A2
(pt)
|
2021-04-06 |
2023-11-14 |
Bristol Myers Squibb Co |
Compostos de oxoisoindolina substituída por piridinila
|
WO2023126531A1
(en)
|
2021-12-31 |
2023-07-06 |
A Fine House S.A. |
Lenalidomide oral solution
|
WO2023126530A1
(en)
|
2021-12-31 |
2023-07-06 |
A Fine House S.A. |
Oral solution comprising lenalidomide
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US11957759B1
(en)
|
2022-09-07 |
2024-04-16 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
|